Silexion Therapeutics近日公布了令人鼓舞的临床前研究数据,证实其候选药物Sil204在系统给药后能够有效到达胰腺癌的主要转移部位并展现出治疗活性。这一研究结果为该公司在胰腺癌治疗领域的药物开发进展提供了重要支撑。
Silexion Therapeutics近日公布了令人鼓舞的临床前研究数据,证实其候选药物Sil204在系统给药后能够有效到达胰腺癌的主要转移部位并展现出治疗活性。这一研究结果为该公司在胰腺癌治疗领域的药物开发进展提供了重要支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.